Thymosin Alpha-1 vs Vilon
Both sit apart from KYIN's tissue-repair peptides as immune-modulation compounds instead — but they land at almost opposite ends of the evidence spectrum, from an internationally approved drug to a single unreplicated animal study.
Neither is currently stocked by KYIN Peptides, but both are available to order — see availability below.
At a Glance
| Thymosin Alpha-1 | Vilon | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Molecular class | 28-amino-acid thymic peptide | Dipeptide (Lys-Glu) — shortest in the Khavinson bioregulator family |
| Proposed mechanism | TLR3/4/9 receptor binding → NF-κB/IRF3 signaling, activating dendritic cells, macrophages, and T-cells | Proposed direct DNA/chromatin binding in thymic tissue, influencing genes governing T-cell maturation |
| Evidence base | Large modern randomized trials, including a 1,106-patient Phase 3 study | One unreplicated 1990s animal lifespan study |
| Human trials | Yes — multiple, including Phase 3 | None |
| Regulatory status | Approved (as thymalfasin/Zadaxin) in 35+ countries for chronic hepatitis B/C; FDA orphan drug designation for several indications | Not evaluated or approved anywhere |
| Available from KYIN Peptides | Available to order (not stocked) | Available to order (not stocked) |
Why They're Grouped Together
Neither compound fits the tissue-repair mechanisms — gastric-protective, actin-driven, or copper-dependent — that define most of KYIN's Healing & Recovery category (BPC-157, TB-500, KPV, GHK-Cu). Instead, both are studied for immune-system modulation and general health — which is why they're grouped together as reference compounds rather than sold alongside the tissue-repair peptides. Beyond that shared "not tissue repair" classification, though, their actual mechanisms don't overlap at all.
How the Mechanisms Differ
Thymosin Alpha-1 works through a defined receptor pathway: it binds TLR3, TLR4, and TLR9 and triggers downstream NF-κB/IRF3 signaling, promoting the maturation and activation of dendritic cells, macrophages, and T-cells. Despite sharing a thymic naming lineage with TB-500's parent molecule (thymosin beta-4), it's a structurally and functionally distinct compound.
Vilon takes a fundamentally different, more speculative approach — the shortest peptide in the Khavinson bioregulator family (the same lineage behind Cartalax and Pinealon), it's proposed to bind DNA directly in thymic tissue and influence gene expression governing T-cell maturation, rather than acting through a conventional cell-surface receptor.
Clinical & Preclinical Trial Data
Thymosin Alpha-1: This is one of the few compounds referenced on this site with a genuinely large, modern randomized trial behind it — and that trial reported a negative result. The ETASS trial (2013, Critical Care; 361 ICU sepsis patients across six Chinese hospitals) found a trend toward improved 28-day survival that did not reach statistical significance (p=0.06). The much larger follow-up TESTS trial (2025, The BMJ; 1,106 sepsis patients, double-blind, placebo-controlled Phase 3) found no significant difference in 28-day mortality versus placebo. Separately from the sepsis research, synthetic Thymosin Alpha-1 (thymalfasin, brand name Zadaxin) is an approved prescription medicine in more than 35 countries for chronic hepatitis B and C, and holds FDA orphan drug designation for several indications in the United States, though it has not received full FDA approval for any indication. See its full research profile.
Vilon: The core evidence is a single, decades-old animal lifespan study (Khavinson & Anisimov, Doklady Biological Sciences): chronic Vilon administration in female CBA mice extended lifespan by 20–40% and reduced the incidence of spontaneous lung adenomas. This has not been independently replicated outside Khavinson-affiliated Russian research, and no human trial of Vilon has been conducted. See its full research profile.
Availability
Neither Thymosin Alpha-1 nor Vilon is part of KYIN Peptides' standard catalogue, but both are available to order — contact us directly and we'll source them for you.
Thymosin Alpha-1 vs Vilon questions
What do Thymosin Alpha-1 and Vilon have in common?
Both sit apart from KYIN's tissue-repair-focused Healing & Recovery peptides (BPC-157, TB-500, KPV, GHK-Cu) — neither works on wound closure or collagen synthesis. Instead, both are studied for immune-system modulation and general health, though through completely different mechanisms.
Which has stronger evidence, Thymosin Alpha-1 or Vilon?
Thymosin Alpha-1, by a wide margin. It has been tested in large modern randomized trials (including a 1,106-patient Phase 3 trial) and is an approved prescription medicine (as thymalfasin/Zadaxin) in more than 35 countries for chronic hepatitis B and C. Vilon's evidence is a single, unreplicated 1990s animal lifespan study, with no human trial ever conducted.
Does KYIN Peptides sell Thymosin Alpha-1 or Vilon?
Neither is part of our standard catalogue, but both are available to order — contact us directly and we'll source them for you.
Interested in sourcing Thymosin Alpha-1 or Vilon?
Contact us and we'll help you source either, or browse our stocked recovery-focused peptides.